Guidelines for forensic urine drug testing will lower the required cannabinoid immunoassay cutoff concentration from 100 to 50 g/L. We investigated the effect of this change on the sensitivity, specificity, and efficiency of eight cannabinoid immunoassays: Syva Emit#{174} d.a.u." 100; Syva Emit 11100; Syva Emit d.a.u. 50; Syva Emit II 50; Roche Abuscreen#{174} OnIine; Roche Abuscreen radioimmunoassay; Diagnostic Reagents#{174}; and Abbott ADx#{174}. All specimens also were assayed by gas chromatography/mass spectrometry. Lowering the cutoff concentration from 100 to 50 pg/L increased efficiencies and sensitivities for all immunoassays, with minor decreases in specificity (1.0-2.6%). There was a 23.2-53.6% increase in the number of true-positive specimens identified.Thus, lowering the cannabinoid immunoassay cutoff concentration from 100 to 50 pg/L resulted in detection of a substantial number of additionaltrue-positive specimens, with an accompanying small increase in unconfirmed positive results.
(THCCOOH).6 Now,
proposed changes to the Guidelines will lower the specified initial test cutoff concentration to 50 gfL, as recommended by the National Institute on Drug Abuse Con- THCCOOH, 11-nor-9-carboxy-9-tetrahydrocannabinol; and THe, 9- Here, we report our study of eight commercial immunoassays to determine the effect of lowering the initial test cutoff concentration from 100 to 50 gfL for cannabinoids in individual urine specimens from six men who participatedin a controlled clinical study of marijuana smoking.
MaterIals and Methods

Samples
Six healthy male subjects with a history of marijuana use resided on the clinical ward of the Addiction Research Center for 4-6 weeks. All subjects provided informed consent and were under continuous medical supervision throughout the study. Subjects smoked a single marijuana cigarette (either placebo, 1.75%, or 3.55% THC) each week. All urine voids were collected, measured, and frozen at -20#{176}C until analyzed.Individual specimen sets were prepared from randomized and coded samples (n = 957) and analyzed under blind conditions by each immunoassay according to the manufacturers' instructions.
An identical set was analyzed by GCIMS at the Navy Drug Screening Laboratory, Jacksonville, FL, by a previously published procedure (3).
Immunoassays
The 
Performance Criteria
For the purposes of this study, the following definitions were applied to evaluate the sensitivity, specificity, and efficiency of each immunoassay at the specified cutoffconcentrations.Assay detectionlimits may be substantially below the mandated cutoff concentration; however, this study is designed to evaluate assay performance at the cutoff concentrations. 
Specificity
All assays were highly specific at both the 100 and 50 pgfL cutoff concentrations ( 
Within-assay comparison
assays at 50 g'L, compared with the d.a.u. 100 and Ell 100 assays at 100 gfL cutoffconcentration, increased efficiency (by 2.6% for the d.a.u. assays and 3.9% for the ElI assays), as shown in Table 2 .
Discussion
To meet the demanding standards required for forensic urine drug testing, a two-tiered system of testing has been devised. The initial assay must be highly sensitive to identi1' presumptive positive specimens, and the second (confirmatory GC/MS) test must be specific to eliminate false-positive results.
The two tests should be based on fundamentally different analytical principles to reduce the impact of potential interferents and to increase confidence in results. Correlation between the initial and confirmatory tests is also an important practicalissue,given the high cost and labor-intensive natare of the confirmatory test. In our study, we demonstrated differing sensitivity and specificity in the d.a.u. and Eli series of reagents. The ElI assays appeared to be more specific for the primary THCCOOH metabolite than were the d.a.u. immunoassays.
The
Decreased specificity in an immunoassay may be desirable in some cases because of the possibility of detecting more true-positive specimens; however, decreased specificity also generates more false-positive results, which requires expensive and labor-intensive confirmation analyses. The urine specimens we analyzed were collected in a controlled clinical study of marijuana smoking. Advantages of using these specimens instead of specimens supplemented to contain only the target analyte include the presence of a variety of conjugated and nonconjugated human cannabinoid metabolites. A further advantage is the information gained from urines collected over an extended time after smoking. The nature and relative concentration of cannabinoid metabolites change over time and a controlled clinical study provides the opportunity to evaluate urines with distinct metabolic patterns.
However, cost, time constraints, and logistical considerations limit the number of subjects who can be studied. Therefore, the number of different sources of urine specimens and the variety of metabolic patterns are limited. Consequently, clinical studies may not reflect the true diversity found in a larger population study. 
